Global Pulmonary Arterial Hypertension (PAH) Industry Research 2023 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Pulmonary Arterial Hypertension Market Research 2023": Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 report has been added to ResearchAndMarkets.com's offering.

The global pulmonary arterial hypertension market was valued at US$8.18 billion in 2022. The market is expected to grow at a CAGR of approx. 6% during the forecasted period of 2023-2028. The market value is expected to reach US$11.43 billion by 2028.

Pulmonary arterial hypertension (PAH) is a rare and progressive disorder characterized by elevated blood pressure of more than 25mmHg in the arteries of the lungs, also known as the pulmonary artery. While PAH affects both genders, it is more prevalent among females aged 30-60 years. Unfortunately, there is no known cure for PAH, but various treatment options are available to manage symptoms and enhance patients' quality of life.

The prevalence of PAH has been increasing over the years, which is contributing to the market growth. It is estimated that 37,000 patients are suffering from PAH in the US in 2022, and a similar number outside the US. Females are more likely to develop PAH, with a female-to-male ratio of 3:1.

There are multiple approved drugs to treat PAH, but all are focused on improving hemodynamics in patients and not treating the underlying disease. New drug candidates target novel pathways that look to address the cause of the disease. On the other hand, therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades.

The advent of pharmacological therapies targeting the prostacyclin, endothelin, and NO pathways has significantly improved outcomes. The development of new and improved therapies for PAH has expanded treatment options and improved patient management.

Also, there have been advancements in the understanding of the underlying mechanisms of PAH, leading to the development of targeted therapies that provide better symptom control and disease management.

Market Segmentation Analysis:

By Drug Class: The report provides the pulmonary arterial hypertension market analysis based on the following drug class: Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), sGC Stimulators, and pde-5 Inhibitors.

The prostacyclin and prostacyclin analogs segment held the highest share in the market, whereas the sGC stimulator is expected to be the fastest-growing segment in the forecasted period. The most commonly used prostacyclin analogs are epoprostenol, treprostinil, and iloprost.

The demand for prostacyclin analogs is increasing as these drugs have demonstrated significant efficacy in improving exercise capacity, reducing symptoms, and delaying disease progression in PAH patients. Their ability to target multiple aspects of the disease makes them valuable treatment options.

On the other hand, sGC stimulators are often used in combination with other PAH-specific drugs, such as endothelin receptor antagonists and prostacyclin analogs, to achieve additive or synergistic effects. The main sGC stimulator currently approved for PAH treatment is riociguat.

By Type: The report provides the bifurcation of the market based on the following types: Branded and Generic.

The branded drugs held the highest share of the market, as pharmaceutical companies invest significant resources in discovering and developing new drugs with novel mechanisms of action, improved efficacy, and better safety profiles.

Generic drugs are expected to be the fastest-growing segment in the forthcoming years as they are generally less expensive than their branded counterparts and undergo regulatory scrutiny to ensure their safety, efficacy, and quality. As healthcare costs continue to rise, the affordability of generic drugs makes them an attractive option for many individuals and organizations.

By Route of Administration: The report provides an analysis of the PAH market based on the following route of administration: Oral, Intravenous/ Subcutaneous, and Inhalation.

The oral segment captured the highest share of the market in 2022, whereas intravenous/ subcutaneous is anticipated to be the fastest-growing segment in the upcoming years. The oral route is convenient for patients as it allows self-administration without the need for healthcare professionals or specialized equipment. This convenience can improve patient compliance and adherence to the prescribed treatment regimen. Whereas, intravenous/ subcutaneous is particularly important for PAH patients in critical condition or during acute exacerbations.

By Distribution Channel: The report offers a glimpse of the PAH market based on the following distribution channel: Hospital Pharmacies and clinics, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies and clinic held the highest share of the market and is expected to be the fastest-growing segment in the forthcoming years. PAH patients may require hospitalization for acute exacerbations, diagnostic procedures, or specialized interventions. In such cases, hospital pharmacies play a crucial role in providing immediate access to medications needed for treatment and monitoring.

Competitive Landscape:

Some of the strategies among key players in the market are new launches, investment in clinical development programs, mergers, acquisitions, and collaborations. Merck (MRK) is strengthening the company's PAH portfolio with Sotatercept.

Merck acquired Sotatercept through its acquisition of Acceleron in 2021. Sotatercept is the first PAH drug to be granted Breakthrough Therapy Designation by FDA or PRIME designation by European Medicines Agency (EMA).

On the other hand, United Therapeutics' Ralinepag is a novel oral IP receptor agonist which is undergoing placebo-controlled Phase 3 trials (Advance Outcomes and Advance Capacity) to determine its effect on time to clinical worsening and exercise capacity.

The global pulmonary arterial hypertension market is moderately concentrated.

Market Dynamics

Growth Drivers

• Rising Number of Female Population
• Growing Prevalence of Lung Cancer and Other Lung Related Disorders
• Increasing Healthcare Expenditure
• Rising Pharmaceutical Research and Development Spending
• Rising Prevalence of PAH
• Availability of Reimbursement

Challenges

• Strict Regulatory Standards
• High Development Cost
• Limited Treatment Options

Market Trends

• New Potential Drugs Development
• Recent Advancements in Treatment
• Technological Advancements
• Increasing Generic Drugs
• Increasing Awareness and Diagnosis of PAH
• Automated Fluid Handling Systems with Machine Learning

The key players in the global pulmonary arterial hypertension market are:

• Bayer AG
• Pfizer Inc.
• Johnson & Johnson
• Novartis AG
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• GlaxoSmithKline Plc.
• TEVA Pharmaceutical Industries Limited
• United Therapeutics Corporation
• Keros Therapeutics, Inc.
• Liquidia Corporation
• Reviva Pharmaceutical Holdings, Inc.
• Resverlogix Corp.
• Tenax Therapeutics
• Aerovate Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ai0li2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900